Physician profile
Vera Bocoun
NPI 1235233560
$3,421.41
in general payments reported to CMS, 2019-2025
13 companies · $91.95 in 2025
The $91.95 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2021: $515 · 2022: $1,214 · 2023: $622 · 2024: $90.34 · 2025: $91.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $804.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $998.97 | 2019-2025 | Rinvoq |
| Janssen Biotech, INC. | $676.99 | 2019-2022 | |
| Amgen INC. | $405.77 | 2022-2023 | Tavneos |
| Janssen Scientific Affairs, LLC | $250.00 | 2022 | |
| Aurinia Pharma U.S., INC. | $219.37 | 2021 | |
| Alexion Pharmaceuticals, INC. | $145.31 | 2022-2023 | Strensiq |
| Pfizer INC. | $134.78 | 2019 | |
| Celgene Corporation | $125.00 | 2019 | |
| Lilly USA, LLC | $122.84 | 2023 | Taltz |
| Novartis Pharmaceuticals Corporation | $118.47 | 2021-2022 | |
| Glaxosmithkline, LLC. | $94.59 | 2021 | |
| Ucb, INC. | $73.96 | 2023 | Cimzia |
| Sobi, INC | $55.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vera Bocoun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.